Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PluroGel N · 1 trial · 2 indications
Clinical Response is defined by the investigator's evaluation of the signs and symptoms of clinical infection.
| Arm | Type | Description |
|---|---|---|
| PluroGel | PLACEBO_COMPARATOR | PluroGel |
| PluroGel N | EXPERIMENTAL | PluroGel N |
| Name | Type | Description |
|---|---|---|
| PluroGel N | DRUG | Study Drug |
| PluroGel | DRUG | PluroGel Vehicle Placebo Comparator |
Inclusion Criteria: * Non-hospitalized subjects with Type 1 or Type 2 diabetes mellitus as defined by the American Diabetes Association diagnostic criteria (ADA, 2010). Diabetes may be treated with insulin, oral hypoglycemic agents, diet, or a combination of these therapies. Subjects whose diabetes...
PluroGel N is an investigational small molecule being studied for the treatment of mildly infected diabetic foot ulcers. It is a topical gel developed by cbdMD, Inc. (YCBD) and is currently in Phase 2 clinical development.
PluroGel N is a small molecule topical gel. Its specific molecular target has not been disclosed. It is being studied for its potential to treat mildly infected diabetic foot ulcers, a condition that involves both wound healing and infection control.
PluroGel N is being developed by cbdMD, Inc., a company traded on the stock exchange under the ticker YCBD. The company is conducting clinical research to evaluate the gel's safety and efficacy for diabetic foot ulcers.
PluroGel N is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 2 trial has been completed, and the drug is not currently in any active clinical trials.
PluroGel N has been studied in one completed Phase 2 clinical trial, NCT02091596, titled 'Topical PluroGel N for the Treatment of Mildly Infected Diabetic Foot Ulcers.' This randomized, double-blind, placebo-controlled trial enrolled 42 participants in the United States.
PluroGel N is the name used in clinical trials for this investigational topical gel. No alternative names have been reported for this drug candidate.